Groff North America makes historic cannabis transaction with DEA

PUBLISHED Feb 23, 2022


CONTACT:       Jay Scott



Groff North America makes historic cannabis transaction with DEA

Pennsylvania company completes first legal transfer/buy-back of domestically cultivated marijuana with federal government

RED LION, Pa. – (February 15, 2022) – Groff North America, a physician-owned hemp-cannabis company based in York County, Pennsylvania, today announced it has become the first company to legally transfer a crop of domestically cultivated marijuana to the U.S. Drug Enforcement Administration.


The February 2nd transfer, which will allow the company to dispense its harvest to clinical researchers and drug developers, was possible because of the DEA’s decision in May 2021 to increase the number of federally registered marijuana manufacturers for the purpose of research. The federal government permitted additional U.S. manufacturers to cultivate and process marijuana for research, pharmaceutical development and pharmaceutical production. For more than 50 years, there was previously only one facility in the U.S. permitted to do so.


Groff North America is one of several manufacturers who were approved to hold schedule 1 registrations for the cultivation, processing, export, import, testing and research of marijuana. This registration allows Groff North America to produce research-grade cannabis and cannabis preparations for sale both in the U.S. and internationally.


“This is a major milestone in the growing field of plant-based medicines. Our ability to supply medical and scientific researchers around the world with high-quality, legal, U.S. manufactured  cannabis products will be a boon to the development of new therapies,” said Steve Groff, M.D., Founder and Chief Medical Officer of Groff North America. “We are on a mission to help unlock the tremendous potential  cannabis-based medicines in the U.S and overseas. Groff North America has shown that our collaboration with the DEA works. We now have a legal pathway to expand research and development of cannabis to meet the increased demand for effective therapeutics.”


“The DEA has become a strong partner in our efforts to expand access to federally approved cannabis for research purposes in the U.S.,” said Joe Grzyb, CEO of Groff North America. “In maintaining strict compliance to U.S. Treaty obligations under the Single Convention on Narcotics, the DEA must take temporary possession of our marijuana harvest. We then immediately purchase back the marijuana flower enabling us to manufacture cannabis preparations (trimmed flower, extracts, and cannabinoid formulations) for sale to federally-approved domestic and international customers.”

Now, as a domestic supplier to DEA-approved companies and researchers, Groff North America will continue manufacturing cannabis for global commerce.

*Photo Caption: Last week, Groff North America became the first company to transfer domestically cultivated marijuana to the DEA. Steve Groff, right, Founder and Chief Medical Officer, and Joe Grzyb, CEO, represented Groff.



Groff North America is a physician-owned cannabis cultivation, extraction and formulation company based in South Central, PA. Founded by Steve Groff, M.D. and lead by Joe Grzyb, CEO, GNA cultivates, processes and refines both cannabis and hemp with a commitment to provide quality, consistent, sustainable, and trusted cannabis products to businesses and researchers who are registered to handle Schedule 1 drugs. GNA is one of three commercially-focused companies with Schedule 1 registrations from the U.S. Drug Enforcement Administration for bulk cultivation of marijuana and the only company to further possess registration for patient dose manufacturing. GNA also has registrations, as cannabis exporter, importer, researcher, and analytical lab. In December of 2021, GNA’s cultivation facility yielded a highly successful first harvest of high quality, medical-grade cannabis. In February 2022, GNA completed the first legal transfer/ buy-back transaction of domestically cultivated marijuana with the DEA, allowing GNA to manufacture and sell its cannabis products for federally authorized research, drug development, drug manufacturing and export. With its seed-to-shelf approach and commitment to technology and human capital, GNA develops products to support customers in the advancement of cannabis-based medicine.

Suggested reads

Jun 22, 2022
Groff NA Presenting at Cannabis Europa
Groff North America is looking forward to speaking at Cannabis Europa London, conference and expo, June 2022. Join me and influential leaders across politics Read more
Apr 20, 2022
Can DEA-backed cannabis growers strike gold via drug development?
Can DEA-backed cannabis growers strike gold via drug development? The cannabis industry hit a possible milestone in March when Bright Green Corp., a Florida Read more
Mar 31, 2022
Groff North America partners with Pennsylvania college for first-of-its-kind cannabinoid major
FOR IMMEDIATE RELEASE CONTACT: Amanda Peterson Martin 484-949-1320 Groff North America partners with Pennsylvania college for first Read more
Mar 04, 2022
How will Groff North America cannabis products be developed from research to market as medicines?
How will Groff North America cannabis products be developed from research to market as medicines? CEO Joe Gryzb talked to Harri Leigh of WPMT FOX43 about the potenti Read more
Mar 03, 2022
We are making history at Groff North America!
We are making history at Groff North America. After 53 years, we are one of five companies approved to grow and study cannabis for medical research in the U.S. WPMT Read more